Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Routine +

Bausch + Lomb Announces Second R&D "Teach-in" Webinar

Bausch + Lomb Pipeline Webinar Confirms Long-Term Growth Narrative, But Near-Term Surgical Headwinds Persist Despite Q1 Guidance Raise

By The Northwire Desk — AI Analysis May 06, 2026 · 07:15 BLCO · 21.85 BAUSCH + LOMB CORPORATION
Executive Summary
  • Bausch + Lomb announced a second R&D "Teach-in" webinar scheduled for June 1, 2026.
  • The event will feature CEO Brent Saunders, CFO Sam Eldessouky, and CMO Yehia Hashad.
  • Focus areas include two specific contact lens technologies: a bioactive contact lens (first new material in 25 years) and a silicone hydrogel daily lens for myopia progression.
  • This follows the April 30 announcement of over 40 scientific studies at ARVO, which also highlighted pipeline assets like BL1107 and BL1312.
  • The webinar is hosted by Citi as part of their "Head, Shoulders, Knees, and Toes" series.
Material Impact
  • The announcement is a follow-up to the Q1 2026 earnings release (April 29) which already raised full-year guidance significantly.
  • Pipeline assets discussed (Bioactive lens, Myopia lens) were previously disclosed in the November 2025 Investor Day presentation with launch timelines of 2028-2029.
  • No new financial data, regulatory approvals, or M&A activity is introduced that would alter the valuation model established in Q1 earnings.
  • The market likely anticipated this communication given the ARVO announcement just days prior and the scheduled Investor Day follow-ups.
  • Impact is incremental to the positive sentiment generated by the Q1 guidance raise; does not constitute a material shift in risk/reward profile.
BLCO · Price
Company Overview
  • Company: Bausch + Lomb Corp., a global eye health company operating in Vision Care, Surgical, and Pharmaceuticals segments.
  • Flagship Projects:
    • Pharmaceuticals: MIEBO (dry eye) and XIIDRA (lifitegrast), driving significant revenue growth (+33% and +30% respectively).
    • Vision Care: LUMIFY (redness reliever) and Biotrue contact lenses; new bioactive lens pipeline in development.
    • Surgical: enVista IOLs, Stellaris Elite systems, and Elios glaucoma laser system.
  • Strategic Focus: Transformation initiative "Vision '27" targeting margin expansion and deleveraging.
Read the original news release →

More from BAUSCH + LOMB CORPORATION

Jul 01, 2026 · 07:00

Dry Eye Survey Reinforces Premium Pricing Power, But Lacks Catalyst to Break Recent Consolidation

Other Jun 01, 2026 · 06:59

Bausch + Lomb Expands Dry Eye Portfolio with Preservative-Free Blink Launch; Execution on $7B Pipeline Continues Amid Margin Expansion

Financings May 19, 2026 · 07:00

Bausch + Lomb Executes H1 2026 Launch Plan Amidst Margin Expansion Push

Other May 07, 2026 · 07:00

Bausch + Lomb Expands Surgical Portfolio with European Bi-Blade+ Launch Amidst Guidance Raise

Other Apr 30, 2026 · 07:00

Bausch + Lomb Pipeline Validation Follows Q1 Guidance Raise Amidst Margin Expansion

Other Apr 29, 2026 · 06:58

Bausch + Lomb Beats Q1 Estimates but Debt Overhang Persists Amid Turnaround Execution

Earnings